HBV cure: why, how, when?

[1]  A. Lok,et al.  Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. , 2016, Journal of hepatology.

[2]  F. Zoulim,et al.  Current treatments for chronic hepatitis B virus infections. , 2016, Current opinion in virology.

[3]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[4]  S. Fletcher,et al.  Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor , 2016, Nature.

[5]  N. Pochet,et al.  A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses , 2016, Hepatology.

[6]  B. Cullen,et al.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9. , 2015, Antiviral research.

[7]  Meghan M. Holdorf,et al.  Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation , 2015, Proceedings of the National Academy of Sciences.

[8]  F. Zoulim,et al.  Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. , 2015, Antiviral research.

[9]  A. Zlotnick,et al.  Core protein: A pleiotropic keystone in the HBV lifecycle. , 2015, Antiviral research.

[10]  E. Schiff,et al.  Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection , 2015, Journal of viral hepatitis.

[11]  C. Coffin,et al.  The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. , 2015, Journal of hepatology.

[12]  K. Caldecott,et al.  Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus Genome Repair? , 2015, PloS one.

[13]  David A. Scott,et al.  CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015, Scientific Reports.

[14]  C. Seeger,et al.  Molecular biology of hepatitis B virus infection. , 2015, Virology.

[15]  C. Begley,et al.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis , 2015, Proceedings of the National Academy of Sciences.

[16]  C. Begley,et al.  Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus , 2015, Proceedings of the National Academy of Sciences.

[17]  R. Kamm,et al.  G04 : Engineered HBV-specific T cells: Disentangling antiviral from killing capacity , 2015 .

[18]  T. Volz,et al.  O115 : High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized uPA/SCID mouse model , 2015 .

[19]  R. Iyer,et al.  P0636 : Antiviral efficacy and induction of host immune responses with SB 9200, an oral prodrug of the dinucleotide SB 9000, in the woodchuck model of chronic hepatitis B virus (HBV) infection , 2015 .

[20]  A. Zlotnick,et al.  P0529 : Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions , 2015 .

[21]  A. Zlotnick,et al.  Anti capsid drugs HAP12 and AT130 target HBV core protein nuclear functions , 2015 .

[22]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[23]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[24]  A. Bertoletti,et al.  Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.

[25]  A. Bertoletti,et al.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections , 2015, Hepatology.

[26]  C. Rice,et al.  The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. , 2015, Immunity.

[27]  C. Ferrari.  HBV and the immune response , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[28]  K. WattsJonathan,et al.  10th Annual Meeting of the Oligonucleotide Therapeutics Society , 2014 .

[29]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[30]  J. Marchand,et al.  TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice , 2014, Gut.

[31]  M. Nassal,et al.  Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses , 2014, Proceedings of the National Academy of Sciences.

[32]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[33]  R. Bartenschlager,et al.  Strategies to inhibit entry of HBV and HDV into hepatocytes. , 2014, Gastroenterology.

[34]  M. Fälth,et al.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. , 2014, Gastroenterology.

[35]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[36]  Wenhui Li,et al.  Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes , 2013, PLoS pathogens.

[37]  M. Aichler,et al.  T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. , 2013, Gastroenterology.

[38]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  R. Lanford,et al.  GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. , 2013, Gastroenterology.

[40]  J. Prieto,et al.  Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis. , 2013 .

[41]  Alan McLachlan,et al.  Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  C. Brander,et al.  Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. , 2013, Journal of hepatology.

[43]  M. Dandri,et al.  Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? , 2013, Journal of hepatology.

[44]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[45]  Wen Chang,et al.  Entry of Hepatitis B Virus into Immortalized Human Primary Hepatocytes by Clathrin-Dependent Endocytosis , 2012, Journal of Virology.

[46]  A. Cuconati,et al.  Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation , 2012, Antimicrobial Agents and Chemotherapy.

[47]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[48]  A. Lohse,et al.  Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation , 2012, Hepatology.

[49]  M. Levrero,et al.  IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. , 2012, The Journal of clinical investigation.

[50]  Fabien Zoulim,et al.  Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. , 2011, Journal of hepatology.

[51]  D. Loeb,et al.  Roles of the Envelope Proteins in the Amplification of Covalently Closed Circular DNA and Completion of Synthesis of the Plus-Strand DNA in Hepatitis B Virus , 2011, Journal of Virology.

[52]  J. Haas,et al.  The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus‐specific CD8+ T‐cell function , 2010, Hepatology.

[53]  M. Maini,et al.  Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection , 2010, PLoS pathogens.

[54]  M. Massari,et al.  Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. , 2010, Gastroenterology.

[55]  F. Zoulim,et al.  Control of hepatitis B virus replication by innate response of HepaRG cells , 2010, Hepatology.

[56]  M. Kann,et al.  Nucleoporin 153 Arrests the Nuclear Import of Hepatitis B Virus Capsids in the Nuclear Basket , 2010, PLoS pathogens.

[57]  M. Levrero,et al.  Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function , 2009, Proceedings of the National Academy of Sciences.

[58]  R. Dwek,et al.  Hepatitis B Virus Requires Intact Caveolin-1 Function for Productive Infection in HepaRG Cells , 2009, Journal of Virology.

[59]  S. Urban,et al.  Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycans , 2007 .

[60]  Tokiko Watanabe,et al.  Involvement of host cellular multivesicular body functions in hepatitis B virus budding , 2007, Proceedings of the National Academy of Sciences.

[61]  M. Levrero,et al.  Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. , 2006, Gastroenterology.

[62]  F. Chisari,et al.  Immunobiology and pathogenesis of viral hepatitis. , 2006, Annual review of pathology.

[63]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[64]  M. Manns,et al.  Structural organization of the hepatitis B virus minichromosome. , 2001, Journal of molecular biology.

[65]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[66]  M. Heikenwalder,et al.  Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. , 2016, Gastroenterology.

[67]  David A. Scott,et al.  CRISPR / Cas 9 cleavage of viral DNA efficiently suppresses hepatitis B virus , 2015 .

[68]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[69]  R. Purcell,et al.  Genomic analysis of the host response to hepatitis B virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.